Molecular Targets Associated with Ulcerative Colitis and the Benefits of Atractylenolides-based Therapy

Overview

Journal Front Pharmacol

Date 2024 Jun 11

PMID 38860174

Authors

Huanzhu Qian

Zhen Ye

Yu Hu

Mingquan Wu

Liulin Chen

Linzhen Li

Zhipeng Hu

Qian Zhao

Chen Zhang

Maoyi Yang

Wen Xudong

Qiaobo Ye

Kaihua Qin

Affiliations

Soon will be listed here.

Abstract

Ulcerative colitis (UC) is a chronic inflammatory disease of the intestines that can significantly impact quality of life and lead to various complications. Currently, 5-aminosalicylic acid derivatives, corticosteroids, immunosuppressants, and biologics are the major treatment strategies for UC, but their limitations have raised concerns. Atractylenolides (ATs), sesquiterpene metabolites found in Koidz., have shown promising effects in treating UC by exerting immune barrier modulation, alleviating oxidative stress, gut microbiota regulation, improving mitochondrial dysfunction and repairing the intestinal barrier. Furthermore, ATs have been shown to possess remarkable anti-fibrosis, anti-thrombus, anti-angiogenesis and anti-cancer. These findings suggest that ATs hold important potential in treating UC and its complications. Therefore, this review systematically summarizes the efficacy and potential mechanisms of ATs in treating UC and its complications, providing the latest insights for further research and clinical applications.

Citing Articles

A pharmacoinformatic approach for studying DC's anticancer potential and control ROS-mediated apoptosis against prostate cancer cells.

Ahn C, Myong J, Ahmed K, Rahman M, Maharub Hossain Fahim M, Choi M Front Oncol. 2025; 15:1471110.

PMID: 39980567 PMC: 11841406. DOI: 10.3389/fonc.2025.1471110.

References

Xu H, Van der Jeught K, Zhou Z, Zhang L, Yu T, Sun Y . Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation. J Clin Invest. 2021; 131(10). PMC: 8121519. DOI: 10.1172/JCI146832. View

Shi Y, Guan S, Tang R, Tao S, Guo D . Simultaneous determination of atractylenolide II and atractylenolide III by liquid chromatography-tandem mass spectrometry in rat plasma and its application in a pharmacokinetic study after oral administration of Atractylodes Macrocephala Rhizoma.... Biomed Chromatogr. 2012; 26(11):1386-92. DOI: 10.1002/bmc.2709. View

Cho H, Kim U, Suh J, Eom H, Kim J, Lee S . Classification of the medicinal plants of the genus Atractylodes using high-performance liquid chromatography with diode array and tandem mass spectrometry detection combined with multivariate statistical analysis. J Sep Sci. 2016; 39(7):1286-94. DOI: 10.1002/jssc.201501279. View

Li C, He L, Jin J . Atractylenolide I and atractylenolide III inhibit Lipopolysaccharide-induced TNF-alpha and NO production in macrophages. Phytother Res. 2007; 21(4):347-53. DOI: 10.1002/ptr.2040. View

Tong X, Zheng Y, Li Y, Xiong Y, Chen D . Soluble ligands as drug targets for treatment of inflammatory bowel disease. Pharmacol Ther. 2021; 226:107859. DOI: 10.1016/j.pharmthera.2021.107859. View

Qu L, Shi K, Xu J, Liu C, Ke C, Zhan X . Atractylenolide-1 targets SPHK1 and B4GALT2 to regulate intestinal metabolism and flora composition to improve inflammation in mice with colitis. Phytomedicine. 2022; 98:153945. DOI: 10.1016/j.phymed.2022.153945. View

Ekhtiar M, Ghasemi-Dehnoo M, Mirzaei Y, Azadegan-Dehkordi F, Amini-Khoei H, Lorigooini Z . The coumaric acid and syringic acid ameliorate acetic acid-induced ulcerative colitis in rats via modulator of Nrf2/HO-1 and pro-inflammatory cytokines. Int Immunopharmacol. 2023; 120:110309. DOI: 10.1016/j.intimp.2023.110309. View

Nakase H, Sato N, Mizuno N, Ikawa Y . The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmun Rev. 2021; 21(3):103017. DOI: 10.1016/j.autrev.2021.103017. View

Ni H, Williams J, Ding W . Mitochondrial dynamics and mitochondrial quality control. Redox Biol. 2014; 4:6-13. PMC: 4309858. DOI: 10.1016/j.redox.2014.11.006. View

10.

Wang R, Wang D, Wang H, Wang T, Weng Y, Zhang Y . Therapeutic Targeting of Nrf2 Signaling by Maggot Extracts Ameliorates Inflammation-Associated Intestinal Fibrosis in Chronic DSS-Induced Colitis. Front Immunol. 2021; 12:670159. PMC: 8387595. DOI: 10.3389/fimmu.2021.670159. View

11.

Cunningham K, Vincent G, Sodhi C, Novak E, Ranganathan S, Egan C . Peroxisome Proliferator-activated Receptor-γ Coactivator 1-α (PGC1α) Protects against Experimental Murine Colitis. J Biol Chem. 2016; 291(19):10184-200. PMC: 4858969. DOI: 10.1074/jbc.M115.688812. View

12.

Le Berre C, Honap S, Peyrin-Biroulet L . Ulcerative colitis. Lancet. 2023; 402(10401):571-584. DOI: 10.1016/S0140-6736(23)00966-2. View

13.

Jiang Z, Peng C, Huang W, Wu B, Zhang D, Ouyang H . A High Throughput Three-step Ultra-performance Liquid Chromatography Tandem Mass Spectrometry Method to Study Metabolites of Atractylenolide-III. J Chromatogr Sci. 2018; 57(2):163-176. DOI: 10.1093/chromsci/bmy098. View

14.

Mirkov M, Verstockt B, Cleynen I . Genetics of inflammatory bowel disease: beyond NOD2. Lancet Gastroenterol Hepatol. 2017; 2(3):224-234. DOI: 10.1016/S2468-1253(16)30111-X. View

15.

Feng W, Ao H, Yue S, Peng C . Systems pharmacology reveals the unique mechanism features of Shenzhu Capsule for treatment of ulcerative colitis in comparison with synthetic drugs. Sci Rep. 2018; 8(1):16160. PMC: 6212405. DOI: 10.1038/s41598-018-34509-1. View

16.

Uzzan M, Martin J, Mesin L, Livanos A, Castro-Dopico T, Huang R . Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity. Nat Med. 2022; 28(4):766-779. PMC: 9107072. DOI: 10.1038/s41591-022-01680-y. View

17.

Wang K, Chen L, Wu C, Chang C, Wang C . Gastroprotective activity of atractylenolide III from Atractylodes ovata on ethanol-induced gastric ulcer in vitro and in vivo. J Pharm Pharmacol. 2010; 62(3):381-8. DOI: 10.1211/jpp.62.03.0014. View

18.

Keller D, Windsor A, Cohen R, Chand M . Colorectal cancer in inflammatory bowel disease: review of the evidence. Tech Coloproctol. 2019; 23(1):3-13. DOI: 10.1007/s10151-019-1926-2. View

19.

Wang C, Duan H, He L . [Absorption kinetics of atractylenolide I in intestines of rats]. Zhongguo Zhong Yao Za Zhi. 2009; 34(11):1430-4. View

20.

Ren Y, Jiang W, Luo C, Zhang X, Huang M . Atractylenolide III Ameliorates TNBS-Induced Intestinal Inflammation in Mice by Reducing Oxidative Stress and Regulating Intestinal Flora. Chem Biodivers. 2021; 18(8):e2001001. DOI: 10.1002/cbdv.202001001. View